The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Folic acid | Cholesterol may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy. |
| Allopurinol | Cholesterol may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy. |
| Oxaliplatin | Cholesterol may increase the excretion rate of Oxaliplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Fluorouracil | Cholesterol may increase the excretion rate of Fluorouracil which could result in a lower serum level and potentially a reduction in efficacy. |
| Testosterone | Cholesterol may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy. |
| Clofarabine | Cholesterol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Riluzole | Cholesterol may increase the excretion rate of Riluzole which could result in a lower serum level and potentially a reduction in efficacy. |
| Sulfasalazine | Cholesterol may increase the excretion rate of Sulfasalazine which could result in a lower serum level and potentially a reduction in efficacy. |
| Glyburide | Cholesterol may increase the excretion rate of Glyburide which could result in a lower serum level and potentially a reduction in efficacy. |
| Leflunomide | Cholesterol may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy. |
| Rosuvastatin | Cholesterol may increase the excretion rate of Rosuvastatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Alvocidib | Cholesterol may increase the excretion rate of Alvocidib which could result in a lower serum level and potentially a reduction in efficacy. |
| Teriflunomide | Cholesterol may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy. |
| Riociguat | Cholesterol may increase the excretion rate of Riociguat which could result in a lower serum level and potentially a reduction in efficacy. |
| Fimasartan | Cholesterol may increase the excretion rate of Fimasartan which could result in a lower serum level and potentially a reduction in efficacy. |
| Delafloxacin | Cholesterol may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy. |
| Brigatinib | Cholesterol may increase the excretion rate of Brigatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Enasidenib | Cholesterol may increase the excretion rate of Enasidenib which could result in a lower serum level and potentially a reduction in efficacy. |
| Testosterone cypionate | Cholesterol may increase the excretion rate of Testosterone cypionate which could result in a lower serum level and potentially a reduction in efficacy. |
| Testosterone enanthate | Cholesterol may increase the excretion rate of Testosterone enanthate which could result in a lower serum level and potentially a reduction in efficacy. |
| Pravastatin | Cholesterol may increase the excretion rate of Pravastatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated estrogens | Cholesterol may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy. |
| Gefitinib | Cholesterol may increase the excretion rate of Gefitinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Cerivastatin | Cholesterol may increase the excretion rate of Cerivastatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Teniposide | Cholesterol may increase the excretion rate of Teniposide which could result in a lower serum level and potentially a reduction in efficacy. |
| Prazosin | Cholesterol may increase the excretion rate of Prazosin which could result in a lower serum level and potentially a reduction in efficacy. |
| Raloxifene | Cholesterol may increase the excretion rate of Raloxifene which could result in a lower serum level and potentially a reduction in efficacy. |
| Celecoxib | Cholesterol may increase the excretion rate of Celecoxib which could result in a lower serum level and potentially a reduction in efficacy. |
| Zidovudine | Cholesterol may increase the excretion rate of Zidovudine which could result in a lower serum level and potentially a reduction in efficacy. |
| Ritonavir | Cholesterol may increase the excretion rate of Ritonavir which could result in a lower serum level and potentially a reduction in efficacy. |
| Vincristine | Cholesterol may increase the excretion rate of Vincristine which could result in a lower serum level and potentially a reduction in efficacy. |
| Methotrexate | Cholesterol may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy. |
| Ivermectin | Cholesterol may increase the excretion rate of Ivermectin which could result in a lower serum level and potentially a reduction in efficacy. |
| Imatinib | Cholesterol may increase the excretion rate of Imatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Sumatriptan | Cholesterol may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy. |
| Tamoxifen | Cholesterol may increase the excretion rate of Tamoxifen which could result in a lower serum level and potentially a reduction in efficacy. |
| Mycophenolate mofetil | Cholesterol may increase the excretion rate of Mycophenolate mofetil which could result in a lower serum level and potentially a reduction in efficacy. |
| Daunorubicin | Cholesterol may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. |
| Nitrofurantoin | Cholesterol may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy. |
| Lamivudine | Cholesterol may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy. |
| Irinotecan | Cholesterol may increase the excretion rate of Irinotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Etoposide | Cholesterol may increase the excretion rate of Etoposide which could result in a lower serum level and potentially a reduction in efficacy. |
| Donepezil | Cholesterol may increase the excretion rate of Donepezil which could result in a lower serum level and potentially a reduction in efficacy. |
| Dactinomycin | Cholesterol may increase the excretion rate of Dactinomycin which could result in a lower serum level and potentially a reduction in efficacy. |
| Ezetimibe | Cholesterol may increase the excretion rate of Ezetimibe which could result in a lower serum level and potentially a reduction in efficacy. |
| Doxorubicin | Cholesterol may increase the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy. |
| Topotecan | Cholesterol may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Tegaserod | Cholesterol may increase the excretion rate of Tegaserod which could result in a lower serum level and potentially a reduction in efficacy. |
| Mitoxantrone | Cholesterol may increase the excretion rate of Mitoxantrone which could result in a lower serum level and potentially a reduction in efficacy. |
| Dasatinib | Cholesterol may increase the excretion rate of Dasatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Camptothecin | Cholesterol may increase the excretion rate of Camptothecin which could result in a lower serum level and potentially a reduction in efficacy. |
| Nilotinib | Cholesterol may increase the excretion rate of Nilotinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Rivaroxaban | Cholesterol may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy. |
| Simeprevir | Cholesterol may increase the excretion rate of Simeprevir which could result in a lower serum level and potentially a reduction in efficacy. |
| Pazopanib | Cholesterol may increase the excretion rate of Pazopanib which could result in a lower serum level and potentially a reduction in efficacy. |
| Apixaban | Cholesterol may increase the excretion rate of Apixaban which could result in a lower serum level and potentially a reduction in efficacy. |
| Vemurafenib | Cholesterol may increase the excretion rate of Vemurafenib which could result in a lower serum level and potentially a reduction in efficacy. |
| Ponatinib | Cholesterol may increase the excretion rate of Ponatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Dabrafenib | Cholesterol may increase the excretion rate of Dabrafenib which could result in a lower serum level and potentially a reduction in efficacy. |
| Afatinib | Cholesterol may increase the excretion rate of Afatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Dolutegravir | Cholesterol may increase the excretion rate of Dolutegravir which could result in a lower serum level and potentially a reduction in efficacy. |
| Sofosbuvir | Cholesterol may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy. |
| Idelalisib | Cholesterol may increase the excretion rate of Idelalisib which could result in a lower serum level and potentially a reduction in efficacy. |
| Palbociclib | Cholesterol may increase the excretion rate of Palbociclib which could result in a lower serum level and potentially a reduction in efficacy. |
| Lenvatinib | Cholesterol may increase the excretion rate of Lenvatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Ombitasvir | Cholesterol may increase the excretion rate of Ombitasvir which could result in a lower serum level and potentially a reduction in efficacy. |
| Tenofovir alafenamide | Cholesterol may increase the excretion rate of Tenofovir alafenamide which could result in a lower serum level and potentially a reduction in efficacy. |
| Osimertinib | Cholesterol may increase the excretion rate of Osimertinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Venetoclax | Cholesterol may increase the excretion rate of Venetoclax which could result in a lower serum level and potentially a reduction in efficacy. |
| Velpatasvir | Cholesterol may increase the excretion rate of Velpatasvir which could result in a lower serum level and potentially a reduction in efficacy. |
| Talazoparib | Cholesterol may increase the excretion rate of Talazoparib which could result in a lower serum level and potentially a reduction in efficacy. |
| Revefenacin | Cholesterol may increase the excretion rate of Revefenacin which could result in a lower serum level and potentially a reduction in efficacy. |
| Duvelisib | Cholesterol may increase the excretion rate of Duvelisib which could result in a lower serum level and potentially a reduction in efficacy. |
| Dacomitinib | Cholesterol may increase the excretion rate of Dacomitinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Glasdegib | Cholesterol may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy. |
| Abemaciclib | Cholesterol may increase the excretion rate of Abemaciclib which could result in a lower serum level and potentially a reduction in efficacy. |
| Alpelisib | Cholesterol may increase the excretion rate of Alpelisib which could result in a lower serum level and potentially a reduction in efficacy. |
| Voxilaprevir | Cholesterol may increase the excretion rate of Voxilaprevir which could result in a lower serum level and potentially a reduction in efficacy. |
| Rucaparib | Cholesterol may increase the excretion rate of Rucaparib which could result in a lower serum level and potentially a reduction in efficacy. |
| Copanlisib | Cholesterol may increase the excretion rate of Copanlisib which could result in a lower serum level and potentially a reduction in efficacy. |
| Tazemetostat | Cholesterol may increase the excretion rate of Tazemetostat which could result in a lower serum level and potentially a reduction in efficacy. |
| Darolutamide | Cholesterol may increase the excretion rate of Darolutamide which could result in a lower serum level and potentially a reduction in efficacy. |
| Lusutrombopag | Cholesterol may increase the excretion rate of Lusutrombopag which could result in a lower serum level and potentially a reduction in efficacy. |
| Pibrentasvir | Cholesterol may increase the excretion rate of Pibrentasvir which could result in a lower serum level and potentially a reduction in efficacy. |
| Glecaprevir | Cholesterol may increase the excretion rate of Glecaprevir which could result in a lower serum level and potentially a reduction in efficacy. |
| Ubrogepant | Cholesterol may increase the excretion rate of Ubrogepant which could result in a lower serum level and potentially a reduction in efficacy. |
| Rimegepant | Cholesterol may increase the excretion rate of Rimegepant which could result in a lower serum level and potentially a reduction in efficacy. |
| Ozanimod | Cholesterol may increase the excretion rate of Ozanimod which could result in a lower serum level and potentially a reduction in efficacy. |
| Tucatinib | Cholesterol may increase the excretion rate of Tucatinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Selumetinib | Cholesterol may increase the excretion rate of Selumetinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Pralatrexate | Cholesterol may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy. |
| Ripretinib | Cholesterol may increase the excretion rate of Ripretinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Fostemsavir | Cholesterol may increase the excretion rate of Fostemsavir which could result in a lower serum level and potentially a reduction in efficacy. |
| Pralsetinib | Cholesterol may increase the excretion rate of Pralsetinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Berotralstat | Cholesterol may increase the excretion rate of Berotralstat which could result in a lower serum level and potentially a reduction in efficacy. |
| Trilaciclib | Cholesterol may increase the excretion rate of Trilaciclib which could result in a lower serum level and potentially a reduction in efficacy. |
| Binimetinib | Cholesterol may increase the excretion rate of Binimetinib which could result in a lower serum level and potentially a reduction in efficacy. |
| Cladribine | The excretion of Cladribine can be increased when combined with Cholesterol. |